HDAC inhibitor,novel and cell-permeable
CAS：287383-59-9
分子式：C18H18N2O4
分子量：326.35
纯度：98%
存储：Store at -20°C

Background:

Scriptaid, identified by a high-throughput transcriptional screening, is a novel histone deacetylase (HDAC) with specific potency towards class I HDACs (50% inhibition concentration IC₅₀values of 0.6 μM for HDAC1 and HDAC3 and 1 μM for HDAC8). Scriptaid shares a similar chemical structure with several others hydroxamic acid-containing HDAC inhibitors (such as TSA and nullscript), which consists of a hydroxamic acid group, an aliphatic chain and an aromatic cap at the other end. Scriptaid has the potential to be used for the treatment of glioblastoma multiforme (GBM), one of the most challenging solid cancers to treat, for its ability to induce apoptosis in glioblastoma cells.

Reference

Sharma V, Koul N, Joseph C, Dixit D, Ghosh S, Sen E. HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med. 2010;14(8):2151-2161.

Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther. 2003;307(2):720-728.

Su GH, Sohn TA, Ryu B, Kern SE. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 2000; 60(12):3137-3142.